ARTIVION, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Artivion reported Q2 2026 revenues of $125.8M (+11% GAAP, +9% constant currency) versus $113.0M in Q2 2025. The company completed its acquisition of Endospan Ltd. (paid $116.7M net cash in May 2026) and received FDA PMA approval for its AMDS Hybrid Prosthesis. However, GAAP net loss was $(13.5)M or $(0.28)/share due to $19.8M in acquisition-related integration and severance expenses; non-GAAP net income was $6.3M or $0.13/share. Adjusted EBITDA grew 7% to $26.4M. The company reiterated full-year 2026 guidance: revenue $480–496M (+7–11% constant currency) and adjusted EBITDA $92–99M, including ~$8M integration expense.
Why this rating
Acquisition materially expands product portfolio in high-priority aortic arch market; adds meaningful M&A integration costs. Moderate impact—acquisition is ~8% of annual revenue guidance, meaningful but manageable for $1.4B company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.